COMMUNIQUÉS West-GlobeNewswire

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
30/03/2026
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of the sale of Cyprium’ [...]
River Oaks Treatment Center Dedicates Its Primary Mental Health Program on World Bipolar Day
30/03/2026
RIVERVIEW, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- Dozens of Riverview community members and mental health providers gathered at River Oaks Treatment Center to mark the ribbon-cutting and dedication of its primary [...]
Vireo Growth Inc. Announces Effectiveness of Management Services Agreement with PharmaCann Inc.
30/03/2026
Management Services Agreement went into effect on March 22, 2026, allowing Vireo to manage certain PharmaCann Colorado assets through closing, which is expected in Q2’26 MINNEAPOLIS, March 30, 2026 (GLOBE NEWSWIRE) -- [...]
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
30/03/2026
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the [...]
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
30/03/2026
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité
30/03/2026
Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025 Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme 1 au 31 décembre 2025 Réalisation d'une [...]
Invivyd Announces Presentation at the World Vaccine Congress Washington
30/03/2026
Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress Washington Presentation titled “Developing mAb Therapies that Keep Pace [...]
Range Impact Reports Full Year 2025 Financial Results
31/03/2026
CLEVELAND, OHIO, March 30, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mine properties [...]
Alvotech files Annual Report with the SEC
31/03/2026
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), [...]
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
30/03/2026
Q4 and FY Revenue of $9.2 million and $38.7 million Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) Q4 and FY [...]
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
30/03/2026
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 [...]
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
30/03/2026
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement, with a 47.5% [...]
INmune Bio Inc. Announces 2025 Results and Provides Business Update
30/03/2026
Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results
30/03/2026
NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to [...]
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
30/03/2026
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first [...]
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
30/03/2026
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, [...]
Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
30/03/2026
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced [...]
Inventiva reports 2025 full year results and provides a business update
30/03/2026
Revenues of €4.5 million for the full year of 2025 Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits 1 as at December 31, 2025 Completed a U.S. registered public offering for gross [...]
IBA – ACQUISITION D’ACTIONS PROPRES
30/03/2026
Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]

Pages